Literature DB >> 7622223

Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.

L Pirofski1, R Lui, M DeShaw, A B Kressel, Z Zhong.   

Abstract

The Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) has been conjugated to tetanus toxoid (GXM-TT) as an investigational vaccine. GXM-TT elicits antibodies that are protective in C. neoformans-infected mice. In an effort to characterize the fine specificity and molecular structure of human GXM-TT-elicited antibodies, we generated two GXM monoclonal antibodies (MAbs) from peripheral blood lymphocytes of a volunteer GXM-TT recipient and studied serum GXM antibody idiotype expression in 10 additional vaccinees. The MAbs, 2E9 and 3B6, are the immunoglobulin M(lambda) isotype and bind capsular polysaccharides of C. neoformans serotypes other than the serotype A that was used for immunization. Neither antibody competes with murine GXM MAbs for antigen binding, suggesting that the human MAbs recognize a different epitope. The B-cell superantigen staphylococcal protein A binds both MAbs, and human immunodeficiency virus gp120 binds 2E9. MAb nucleic acid sequence analysis revealed that both antibodies use an identical V lambda 1a-J lambda genetic element with different, somatically mutated, members of the VH3 gene family and different DH and JH gene elements. The gene elements used by both MAbs occur in fetal B-lymphocyte repertoires, autoantibodies, and other polysaccharide antibodies. Post-GXM-TT vaccination GXM antibodies from 10 additional vaccinees expressed a shared idiotype defined by rabbit antiserum raised against MAb 2E9. Our data suggest that the human GXM antibody response is restricted and raise questions regarding the importance of specific variable-region elements and superantigens in the generation of human antibody responses to encapsulated pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622223      PMCID: PMC173409          DOI: 10.1128/iai.63.8.3005-3014.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

Review 1.  Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future.

Authors:  J B Robbins
Journal:  Immunochemistry       Date:  1978-11

2.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

3.  Effects of HIV infection on VH3 (D12 idiotope) B cells in vivo.

Authors:  L Berberian; J Shukla; R Jefferis; J Braun
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-07

4.  Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis.

Authors:  D K Henderson; J E Bennett; M A Huber
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

5.  A human anti-insulin IgG autoantibody apparently arises through clonal selection from an insulin-specific "germ-line" natural antibody template. Analysis by V gene segment reassortment and site-directed mutagenesis.

Authors:  Y Ichiyoshi; M Zhou; P Casali
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

6.  Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.

Authors:  T R Kozel; E Reiss; R Cherniak
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

Review 7.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

8.  Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.

Authors:  D C Houpt; G S Pfrommer; B J Young; T A Larson; T R Kozel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

9.  Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.

Authors:  J Mukherjee; G Nussbaum; M D Scharff; A Casadevall
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

10.  Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae.

Authors:  D E Briles; C Forman; S Hudak; J L Claflin
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  31 in total

1.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.

Authors:  G Nussbaum; S Anandasabapathy; J Mukherjee; M Fan; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 3.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

4.  Relationship of virulence factor expression to evolved virulence in mouse-passaged Cryptococcus neoformans lines.

Authors:  Erin E McClelland; Wesley T Perrine; Wayne K Potts; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 5.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

6.  Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.

Authors:  A Nakouzi; P Valadon; J Nosanchuk; N Green; A Casadevall
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition.

Authors:  Cory L Brooks; Sven Müller-Loennies; Svetlana N Borisova; Lore Brade; Paul Kosma; Tomoko Hirama; C Roger Mackenzie; Helmut Brade; Stephen V Evans
Journal:  Biochemistry       Date:  2010-01-26       Impact factor: 3.162

9.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Lupus-specific antibodies reveal an altered pattern of somatic mutation.

Authors:  A J Manheimer-Lory; G Zandman-Goddard; A Davidson; C Aranow; B Diamond
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.